Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: Analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D)

Trials

Volumn 16, Issue 1, 2015, Pages

  Heywood, James ^a   Evangelou, Marina ^a   Goymer, Donna ^a   Kennet, Jane ^a   Anselmiova, Katerina ^a   Guy, Catherine ^a   O'Brien, Criona ^a   Nutland, Sarah ^b   Brown, Judy ^a   Walker, Neil M ^a   Todd, John A ^a   Waldron Lynch, Frank ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Disease register; Interleukin 2; Internet; Recruitment; Type 1 diabetes

Indexed keywords

ALDESLEUKIN; INTERLEUKIN 2;

ADULT; AGE; ARTICLE; COMPARATIVE STUDY; DISEASE DURATION; DISEASE REGISTRY; EUROPEAN UNION; FEMALE; GEOGRAPHIC DISTRIBUTION; HOSPITAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERNET; MAJOR CLINICAL STUDY; MALE; MASS MEDIUM; MEDICAL RESEARCH; PARTICIPANT RECRUITMENT; PARTICIPATORY MANAGEMENT; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL; REGULATORY T LYMPHOCYTE; RESEARCH SUBJECT; SINGLE DRUG DOSE; SOCIAL WELFARE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; PATIENT SELECTION;

ADULT; CHARITIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INTERLEUKIN-2; INTERNET; MALE; PATIENT SELECTION; T-LYMPHOCYTES, REGULATORY;

EID: 84928226486     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0583-7     Document Type: Article

References (37)

1. Association of Medical Research Charities, Ipsos MORI. Public support for research in the NHS. Association of Medical Research Charities. June 2011. https://www.ipsos-mori.com/researchpublications/researcharchive/2811/Public-support-for-research-in-the-NHS.aspx Accessed 15 Feb 2015.
2. Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;311(10):1045-51.
3. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. 2012;2(1):e000496.
4. Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 2010;11:78.
5. Shere M, Zhao XY, Koren G. The role of social media in recruiting for clinical trials in pregnancy. PLoS One. 2014;9(3):e92744.
6. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027-33.
7. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82.
8. Group DCaCTR. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46(2):271-86.
9. Liu E, Eisenbarth GS. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am. 2002;31(2):391-410. vii-viii.
10. Steffes MW, Sibley S, Jackson M, Thomas W. beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832-6.
11. Barnard K, Thomas S, Royle P, Noyes K, Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr. 2010;10:50.
12. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol. 2004;4(12):989-97.
13. Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov. 2011;10(6):439-52.
14. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry Jr RJ, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487-97.
15. Waldron-Lynch F, Kareclas P, Irons K, Walker NM, Mander A, Wicker LS, et al. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open. 2014;4(6):e005559.
16. ImmunoBase. Juvenile Diabetes Research Foundation International and the Wellcome Trust, United Kingdom. 2001. http://www.immunobase.org Accessed 15 Feb 2015.
17. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009;41(9):1011-5.
18. Ahmed ST, Akirav E, Bradshaw E, Buckner J, McKinney E, Quintana FJ, et al. Immunological biomarkers: catalysts for translational advances in autoimmune diabetes. Clin Exp Immunol. 2013;172(2):178-85.
19. MacAllister R, Veighey K. Governing mechanistic studies to understand human biology. Res Ethics. 2012;8(4):212-5.
20. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295-305.
21. Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22(7):1388-95.
22. Waldron-Lynch F. Adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency) NCT02265809 https://clinicaltrials.gov/ct2/show/NCT02265809 2014. Accessed 15 Feb 2015.
23. NIHR Clinical Research Network. Participant Identification Centres PICS. 2013. http://www.cso.scot.nhs.uk/wp-content/uploads/2013/06/PICs-leaflet.pdf Accessed 15 Feb 2015.
24. ADDRESS2: Supporting Type 1 Diabetes Research. Diabetes Research Network and Medicines for Children Research Network, United Kingdom. 2011. http://www.address2.org Accessed 15 Feb 2015.
25. UK Clinical Research Network Portfolio Database: Diabetes - Genes, Autoimmunity and Prevention (D-GAP). 2011. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=5798 Accessed 15 Feb 2015.
26. Juvenile Diabetes Research Foundation. Can interleukin-2 stop further damage to the pancreas in type 1 diabetes? (DILT1D study). 2013. http://www.jdrf.org.uk/research/getting-involved-in-research/current-trials/adaptive-study-of-il-2-dose-on-regulatory-t-cells-in-type-1-diabetes-dil-t1d Accessed 15 Feb 2015.
27. Diabetes UK. Rebalancing the Immune System in Type 1 Diabetes. 2013. http://www.diabetes.org.uk/Research/Take-part-in-research/Rebalancing-the-immune-system-in-Type-1-diabetes/ Accessed 5 September 2014.
28. Juvenile Diabetes Research Foundation. Successful JDRF-funded clinical trial continues to recruit participants. Jan 2014. http://www.jdrf.org.uk/news/latest-news/successful-jdrf-funded-clinical-trial-continues-to-recruit-participants Accessed 15 Feb 2015.
29. University of Cambridge. Genetic studies lead to clinical trial of new treatment for type 1 diabetes. 2013. http://www.cam.ac.uk/research/news/genetic-studies-lead-to-clinical-trial-of-new-treatment-for-type-1-diabetes Accessed 15 Feb 2015.
30. Department for Communities and Local Government. The English Indices of Deprivation 2010: technical report. 2011. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010-technical-report Accessed 15 Feb 2015.
31. Department for Communities and Local Government. Open Access to Local Data: Societal Wellbeing. 2014. http://opendatacommunities.org/resource?uri=http%3A%2F%2Fopendatacommunities.org%2Fdef%2Fconcept%2Ffolders%2Fthemes%2Fsocietal-wellbeing Accessed 15 Feb 2015.
32. GoogleAnalytics. Google, California. 2005. http://www.google.com/analytics/ Accessed 15 Feb 2015.
33. Bailey NT. Statistical Methods in Biology. 3rd ed. Cambridge: Cambridge University Press; 1995.
34. Gale EAM, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3-15.
35. Kadhim Shubber: Type 1 diabetes treatment could reduce need for insulin injections. Wired.co.uk. 2013. http://www.wired.co.uk/news/archive/2013-06/11/type-1-diabetes-treatment Accessed 15 Feb 2015.
36. Treweek S, Wilkie E, Craigie AM, Caswell S, Thompson J, Steele RJ, et al. Meeting the challenges of recruitment to multicentre, community-based, lifestyle-change trials: a case study of the BeWEL trial. Trials. 2013;14:436.
37. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.